Glucagon-like peptide-2 relaxes mouse stomach through vasoactive intestinal peptide release

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 296, Issue 3, 2009, Pages

  Amato, Antonella ^a   Baldassano, Sara ^a   Serio, Rosa ^a   Mulè, Flavia ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Enteric nervous system; Gastric fundus; Gastric motility; Gastrointestinal hormones

Indexed keywords

APAMIN; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL; CARBACHOL; CHYMOTRYPSIN A; GLUCAGON LIKE PEPTIDE 2; ISOPRENALINE; NITRIC OXIDE SYNTHASE; OMEGA CONOTOXIN; SODIUM CHANNEL; TETRODOTOXIN; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA-CHYMOTRYPSIN; CHYMOTRYPSIN; ENZYME INHIBITOR; N(G) NITROARGININE METHYL ESTER; SODIUM CHANNEL BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GASTROINTESTINAL TRACT; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; STOMACH FUNCTION; STOMACH MUCOSA; ANIMAL; C57BL MOUSE; DRUG EFFECT; INNERVATION; INTESTINE INNERVATION; METABOLISM; PHYSIOLOGY; STOMACH ANTRUM; STOMACH EMPTYING; STOMACH FUNDUS;

ANIMALS; CHYMOTRYPSIN; ENTERIC NERVOUS SYSTEM; ENZYME INHIBITORS; GASTRIC EMPTYING; GASTRIC FUNDUS; GLUCAGON-LIKE PEPTIDE 2; ISOPROTERENOL; MALE; MICE; MICE, INBRED C57BL; NG-NITROARGININE METHYL ESTER; PYLORIC ANTRUM; SODIUM CHANNEL BLOCKERS; SYMPATHOMIMETICS; TETRODOTOXIN; VASOACTIVE INTESTINAL PEPTIDE;

EID: 65349159856     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.90587.2008     Document Type: Article

References (29)

1. Bjerknes M, Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci USA 98: 12497-12502, 2001.
2. Bozkurt A, Näslund E, Holst JJ, Hellström PM. GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat. Regul Pept 107: 129-135, 2002.
3. Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol Endocrinol Metab 272: E1050-E1058, 1997.
4. De Luca A, Li CG, Rand MJ, Reid JJ, Thaina P, Wong-Dusting HK. Effects of ω-conotoxin GVIA on autonomic neuroeffector transmission in various tissues. Br J Pharmacol 101: 437-447, 1990.
5. Demchyshyn LL, Hong W. Teduglutide (ALX-0600), a Glucagon-like peptide-2 (GLP-2) analogue inhibits contractility in the colon ex vivo (Abstract). Gastroenterology 130: W1605, 2006.
6. Dubé PE, Brubaker PL. Forntiers in glucagons-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 293: E460-E465, 2007.
7. Estall JL, Yusta B, Drucker DJ. Lipid raft-dependent glucagon-like peptide-2 receptor trafficking occurs independently of agonist-induced desensitization. Mol Biol Cell 15: 3673-3687, 2004.
8. Guan X, Karpen HE, Stephens J, Bukowski JT, Niu S, Zhang G, Stoll B, Finegold M, Holst JJ, Hadsell DL, Nichols B, Burrin DG. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 130: 150-164, 2006.
9. Hartmann B, Johnsen AH, Orskov C, Adelhorst K, Thim L, Holst JJ. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 21: 73-80, 2000.
10. Jeppesen PB. Glucagon-like peptide-2: update of the recent clinical trials. Gastroenterology 130: S127-S131, 2006.
11. Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ, Mortensen PB. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 120: 806-815, 2001.
12. Maggi CA, Patacchini AR, Santicioli P, Lippe IT, Giuliani S, Geppetti P, Del Bianco E, Selleri S, Meli A. The effect of ω-conotoxin GVIA, a peptide modulator of the N-type voltage sensitive calcium channels, on motor responses produced by activation of efferent and sensory nerves in mammalian smooth muscle. Naunyn Schmiedebergs Arch Pharmacol 334: 172-180, 1988.
13. Mashimo H, He XD, Huang PL, Fishman MC, Goyal RK. Neuronal constitutive nitric oxide synthase is involved in murine enteric inhibitory neurotransmission. J Clin Invest 98: 8-13, 1996.
14. Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, Bulut K, Schmidt WE, Gallwitz B, Holst JJ. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 130: 44-54, 2006.
15. Mulè F, Serio R. NANC inhibitory neurotransmission in mouse isolated stomach: involvement of nitric oxide, ATP and vasoactive intestinal polypeptide. Br J Pharmacol 140: 431-437, 2003.
16. Mulè F, Naccari D, Serio R. Evidence for the presence of P2y and P2x receptors with different functions in mouse stomach. Eur J Pharmacol 513: 135-140, 2005.
17. Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshin L, Yang ZJ, Kamboi RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ, Crivici A. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 96: 1569-1573, 1999.
18. Nagell CF, Wettergren A, Pedersen JF, Mortensen D, Holst JJ. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand J Gastroenterol 39: 353-358, 2004.
19. Orskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 124: 105-112, 2005.
20. Schmidt PT, Näslund E, Grybäck P, Jacobsson H, Hartmann B, Holst JJ, Hellström PM. Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept 116: 21-25, 2003.
21. Shin ED, Estall JL, Izzo A, Drucker DJ, Brubaker PL. Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology 128: 1340-1353, 2005.
22. Sigalet DL, Wallace LE, Holst JJ, Martin GR, Kaji TK, Tanaka H, Sharkey KA. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 293: G211-G221, 2007.
23. Tang-Christensen M, Larsen PJ, Thulesen J, Rømer J, Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 6: 802-807, 2000.
24. Thulesen J, Knudsen LB, Hartmann B, Hastrup S, Kissow H, Jeppesen PB, Ørskov C, Holst JJ, Poulsen SS. The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regul Pept 103: 9-15, 2002.
25. Wallis K, Walters JRF, Forbes A. Glucagon-like peptide 2 - current applications and future directions. Aliment Pharmacol Ther 25: 365-372, 2007.
26. Walsh NA, Yusta B, DaCambra MP, Anini Y, Drucker DJ, Brubaker PL. Glucagon-like peptide-2 receptor activation in the rat intestinal mucosa. Endocrinology 144: 4385-4392, 2003.
27. Wøjdemann M, Wettergren A, Hartmann B, Holst JJ. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 33: 828-832, 1998.
28. Xiao Q, Boushey RP, Drucker DJ, Brubaker PL. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 117: 99-105, 1999.
29. Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, Sharma S, Demchyshyn L, Asa SL, Drucker DJ. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 119: 744-755, 2000.